|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:ATCCode
|
L01EB01
|
|
gptkbp:brand
|
gptkb:Iressa
|
|
gptkbp:CASNumber
|
gptkb:137234-62-9
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:drugClass
|
gptkb:antineoplastic_agent
|
|
gptkbp:hasBindingDBID
|
gptkb:BTB00013
|
|
gptkbp:hasInChIKey
|
gptkb:YGJQOFRFGKYBSF-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C22H24ClFN4O3
|
|
gptkbp:hasPatent
|
gptkb:US5714511A
|
|
gptkbp:hasSMILES
|
COC1=CC2=C(C=C1)N=C(NC3=CC(=C(C=C3)Cl)F)C=C2OCCCN4CCOCC4
|
|
gptkbp:hasUNII
|
N9U0A0A0F0
|
|
gptkbp:IUPACName
|
gptkb:N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
|
|
gptkbp:KEGGID
|
gptkb:D01977
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:EGFR_tyrosine_kinase_inhibitor
|
|
gptkbp:molecularWeight
|
446.90 g/mol
|
|
gptkbp:name
|
gptkb:Gefitinib
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL941
110048
123631
DB00317
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
skin rash
|
|
gptkbp:status
|
FDA approved
|
|
gptkbp:usedFor
|
treatment of non-small cell lung cancer
|
|
gptkbp:bfsParent
|
gptkb:voriconazole
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
137234-62-9
|